Introduction
Infection, toxicities of chemo-radiotherapy and GVHD each contribute to the occurrence of pulmonary disease as a relatively common complication of allogeneic hematopoietic stem cell transplantation (HSCT). Furthermore, longterm survivors of chronic GVHD are known to be at risk for the development of significant obstructive pulmonary disease. Bronchiolitis obliterans (BO), also known as constrictive bronchiolitis or obliterative bronchiolitis is the most common late noninfectious pulmonary complication following allogeneic HSCT. It is characterized by the onset of new airflow obstruction following HSCT. 1, 2 Eosinophilic pulmonary syndrome is an uncommon problem in SCT recipients, and is a clinically and pathologically distinct entity from the classic eosinophilic pneumonias such as Lo¨effler syndrome, acute eosinophilic pneumonia, bronchopulmonary aspergillosis and hypereosinophilic syndrome. The latter entities are characterized by filling of the alveolar spaces by eosinophils, 3 whereas eosinophilic pulmonary syndrome following HSCT involves the small airways. A similar phenomenon, described in lung transplant recipients, is associated with an unfavorable prognosis, and it has been proposed that peripheral eosinophilia can be a sign of lung allograft rejection. 4 The clinical manifestations of eosinophilic pulmonary syndrome are variable; however, the histopathological findings in the lungs are characterized by acute bronchiolitis with eosinophilic infiltration of the bronchiolar walls. A peripheral eosinophilia is usually observed in these patients. Previous reports regarding long-term outcome and complications for SCT patients with eosinophilic pulmonary syndrome are limited 5, 6 We report three cases of eosinophilic pulmonary syndrome, which may be a rare manifestation of pulmonary GVHD following allogeneic SCT.
Case reports

Case 1
A 56-year-old Caucasian man with relapsed diffuse large B-cell lymphoma underwent allogeneic HSCT from an HLA-matched sibling donor following a myeloablative conditioning regimen of CY and 1200 cGy TBI. Previous therapies included rituximab, CY, doxorubicin, vincristine and prednisone (R-CHOP) and rituximab, ifosfamide, carboplatin and etoposide (R-ICE). GVHD prophylaxis consisted of tacrolimus and mycophenolate mofetil. Approximately 3 weeks post transplant he developed grade II acute skin GVHD, which responded to tapering doses of corticosteroids. At about 12 months post transplant he developed sclerodermatous skin changes as well as peripheral blood eosinophilia (28% of leukocytes or 4256 eosinophils per ml). He was treated with prednisone and photopheresis. Following completion of a steroid taper, at approximately 41 months post transplant, he presented with progression of his sclerodermatous skin changes, as well as dyspnea on exertion and cough. At the time of presentation he was undergoing photopheresis but was taking no systemic immunosuppressive drug therapy. He had no fever, chills, hemoptysis or chest pain. Antimicrobial prophylaxis at that time consisted of levaquin, posaconazole and thrice weekly trimethoprim/sulfamethoxasole. Physical examination on presentation revealed tachypnea and inspiratory crackles at the lung bases and sclerodermatous skin changes over his flanks and arms, which had increased in surface area extent compared with the previous visit. Laboratory studies showed significant eosinophilia (13% or 1989 eosinophils per ml). Pulmonary function tests (PFTs) showed a forced expiratory volume in 1 s (FEV1) of 2.58 L (69% predicted) and a forced vital capacity (FVC) of 3.74 (76% predicted). Diffusing capacity of the lung for carbon monoxide (DLCO) was 13.4 mL/ mmHg/min (46% predicted). A computed tomography (CT) chest scan revealed patchy ground glass opacities and centrilobular tree-in-bud infiltrates in the both lower lobes, consistent with bronchiolitis. The patient underwent videoassisted thoracoscopic (VATS) lung biopsy which revealed marked neutrophilic and eosinophilic infiltration within the lumena and walls of medium sized bronchi and bronchioles indicating acute bronchitis/bronchiolitis with eosinophilia ( Figure 1a ). All stains and cultures for bacterial, fungal, and viral organisms and pneumocystis were negative. The pulmonary parenchyma showed thickened blood vessel walls raising the question of pulmonary hypertension. The patient was started on prednisone 1 mg/kg/day and azithromycin 500 mg/day and his eosinophilia and pulmonary symptoms improved rapidly. The prednisone was gradually tapered, with continued improvement in exercise tolerance. Follow-up PFTs and CT scans also improved over time. He had one exacerbation of his pulmonary symptoms several months later, which responded to reinstitution of corticosteroid therapy. Unfortunately, the patient died about 8 months after his initial pulmonary presentation, due to hospital-acquired pneumonia.
Case 2
A 38-year-old Caucasian man with anaplastic T-cell lymphoma underwent HLA-matched sibling allogeneic HSCT following a myeloablative conditioning regimen of CY and 1200 cGy TBI. Previous therapies included CHOP and etoposide, methylprednisolone, cytarabine and cisplatinum (ESHAP). GVHD prophylaxis consisted of tacrolimus and mycophenolate mofetil. He had clinical grade I acute skin GVHD in the early post-transplant period. Approximately 4 months post transplant he presented with acute dyspnea and cough with diffuse pulmonary infiltrates on chest X-ray. Antimicrobial prophylaxis at that time consisted of acyclovir, thrice weekly trimethoprim/sulfamethoxasole and fluconazole. He was being treated with topical steroids for mild chronic GVHD. Physical examination revealed tachypnea and inspiratory crackles; there were also new skin changes including an erythematous rash involving his upper trunk, posterior thorax and upper extremities consistent with active chronic GVHD and lichenoid changes on the buccal mucosa. He was afebrile and the rest of physical exam was normal. Laboratory studies revealed significant eosinophilia (25% of leukocytes or 1932 eosinophils per ml). Spirometry showed an FEV1 OF 49% predicted and a DLCO of 48% of predicted. Chest X-ray revealed diffuse bilateral reticulonodular infiltrates, and a CT scan showed diffuse pulmonary infiltrates with a tree-inbud appearance consistent with bronchiolitis. The patient underwent VATS lung biopsy, which showed BO with eosinophilic infiltration and focal organization (Figure 1b) . All stains and cultures for bacterial, fungal and viral organisms, and pneumocystis were negative. He was started on prednisone 2 mg/kg/day with rapid clinical improvement and disappearance of blood eosinophilia. He developed steroid-induced mania and myopathy, so steroids were Eosinophilic pulmonary syndrome M Akhtari et al tapered rapidly. His pulmonary symptoms returned in less than 2 months so he was restarted on prednisone, in combination with infliximab, which resulted in improvement of his pulmonary symptoms. After 3 months, CT of the chest revealed clear lung parenchyma. He is alive 53 months after his HSCT, off of all immunosuppression, without pulmonary complaints or other signs of active GVHD.
Case 3
A 57-year-old Caucasian man with AML underwent allogeneic HSCT from a matched unrelated donor following a nonmyeloablative conditioning regimen of fludarbine and single fraction TBI (200 cGy). Previous therapies included cytarabine and daunorubicin. GVHD prophylaxis consisted of tacrolimus and mycophenolate mofetil. Approximately 2 months post transplant, he developed acute GVHD of the gastrointestinal tract and skin, which responded to corticosteroids. After completion of a steroid taper, tacrolimus was discontinued at about 9 months post transplant because of renal insufficiency and he remained on mycophenolate mofetil. He had developed chronic skin GVHD and lichenoid changes in his oropharynx. At approximately 11 months post transplant, the patient presented with acute dyspnea, cough and bilateral pulmonary infiltrates. He also had new symptoms and signs of chronic skin GVHD including an erythematous rash over his face with fine desquamation and ocular GVHD with dry eyes. He was only taking mycophenolate mofetil at the time of presentation. Antimicrobial prophylaxis consisted of thrice weekly trimethoprim/sulfamethoxasole, acyclovir and voriconazole. Laboratory studies were notable for a complete blood count showing eosinophilia (11% of leukocytes or 891 eosinophils per ml). CT scan of the chest showed ground glass opacities with nodularity in the upper lobes bilaterally. The patient underwent VATS with lung biopsy, which revealed multifocal organizing pneumonitis with focal BO. In addition, there was a prominent multifocal small and medium vessel vasculitis with eosinophils ( Figure 1c ). All stains and cultures for bacterial, fungal and viral organisms and pneumocystis were negative. He was started on prednisone 2 mg/kg/day with rapid clinical improvement and disappearance of the eosinophilia. During tapering of the steroids, he developed a flare of his chronic GVHD of the skin, which responded to an increased steroid dose. He is currently without active GVHD, maintained on mycophenolate mofetil alone.
Discussion
These three patients developed eosinophilic pulmonary syndrome with blood eosinophilia as a late complication following allogeneic HSCT. The pulmonary histology, obtained in each case by a VATS lung biopsy, is distinct, with evidence of acute lung injury in the form of bronchiolitis or bronchitis with prominent eosinophilia. None of the cases showed pure BO or constrictive bronchiolitis, as is more typically seen as a manifestation of chronic GVHD. All three patients had either a history of previous chronic GVHD or presented with other concurrent manifestations of chronic GVHD, notably skin involvement in all patients. All three patients received TBI as part of their conditioning regimen; however, cases 1 and 2 had 1200 cGy TBI as part of a myeloablative conditioning regimen, whereas case 3 had 200 cGy as part of a nonmyeloablative conditioning regimen. There were no common elements of therapy before the transplant maneuver.
The role of eosinophils in acute and chronic GVHD is a matter of speculation. Activated eosinophils have been found in the upper gastrointestinal tract of patients with GVHD. The presence of eosinophils in duodenal biopsy specimens taken during acute flare ups correlates with gut graft-versus-host-reaction severity, and may be a general marker of acute GVHD flares. 7 There are prospective data on the predictive value of BM eosinophils in the development of acute GVHD. 8 Moreover, there is also evidence that eosinophils show signs of activation in both blood and target organs of patients during acute flares of GVHD. The presence of upregulated CD25 on eosinophils in the blood probably represents activation of donor-derived eosinophils in the context of GVHD. 9, 10 Blood eosinophilia has also been associated with progression to chronic GVHD, and an increased probability of developing sclerodermatous GVHD. [11] [12] [13] Peripheral eosinophilia and eosinophilic infiltrates have also been described in the setting of solid organ transplantation, and are almost always associated with graft rejection. In liver 14 and lung 4 transplant recipients, graft infiltration by eosinophils is known to be a sensitive marker of rejection. An association among peripheral eosinophilia, graft eosinophilia and rejection has also been reported in renal transplant recipients. 15 Blood eosinophilia is a marker of cardiac rejection, and the degree of eosinophilia correlates with severity of rejection. 4 Common findings among these three patients' eosinophilic pulmonary syndrome following HSCT included male sex, use of blood HPC rather than BM, previous or concurrent active chronic GVHD involving skin, peripheral blood eosinophilia and the occurrence of the pulmonary syndrome after day 100 post transplant ( Table 1) . The pathological findings demonstrate common features including the presence of tissue eosinophilia, bronchiolitis Eosinophilic pulmonary syndrome M Akhtari et al and organization. Case 2 also had features of a pronounced eosinophilic vasculitis, which was absent in the other two cases (Table 2 ). These pathological features correlated with the occurrence of a new obstructive pattern on PFTs, which initially suggested BO syndrome, as is commonly seen in lung transplant recipients with chronic graft failure. 16 It is unlikely that these patients' pulmonary findings are a consequence of previous chemotherapies, given the timing of the presentations, association with chronic GVHD and common pathologic findings.
In conclusion, we report three cases of acute eosinophilic pulmonary syndrome as a rare manifestation of pulmonary GVHD in HSCT recipients for hematological disorders. These patients responded favorably to steroids and infliximab, indicating significant reversibility of the syndrome if treated promptly. Peripheral eosinophilia and pulmonary symptoms should be identified, evaluated and treated promptly to prevent the development of irreversible and debilitating chronic GVHD changes. Given the clinical overlap with infectious pneumonitis, tissue biopsy is typically necessary for definitive diagnosis. 
